10x Genomics (TXG) Cash from Operations (2018 - 2026)

10x Genomics has disclosed Cash from Operations across 9 years of filings, most recently posting 26120000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 26120000.0, down 23.96% year-over-year; the trailing twelve-month figure through Mar 2026 was 127819000.0 (up 125.27% YoY), and the FY2025 annual result was 136050000.0, up 1941.57% from the prior year.
• Cash from Operations came in at 26120000.0 for Q1 2026 at 10x Genomics, down from 40777000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 43214000.0 in Q3 2025 to a low of 25304000.0 in Q3 2023.
• The 5-year median for Cash from Operations is 7496000.0 (2024), against an average of 7060647.06.
• Across the five-year window, Cash from Operations slumped 643.69% in 2022 and soared 704.28% in 2025, its largest moves.
• 10x Genomics' Cash from Operations stood at 13723000.0 in 2022, then surged by 87.7% to 25758000.0 in 2023, then sank by 126.2% to 6748000.0 in 2024, then jumped by 704.28% to 40777000.0 in 2025, then tumbled by 35.94% to 26120000.0 in 2026.
• The last three Cash from Operations figures came in at 26120000.0 (Q1 2026), 40777000.0 (Q4 2025), and 43214000.0 (Q3 2025), per Business Quant data.